Aimovig (erenumab-aooe) is a monoclonal antibody used for the preventive treatment of migraines in adults. It is the first FDA-approved drug in its class to target and block the calcitonin gene-related peptide (CGRP) receptor, which plays a critical role in migraine development.

By inhibiting the CGRP receptor, Aimovig helps prevent migraine attacks before they start, reducing their frequency, duration, and severity.

How it's used:

• Given as a once-monthly subcutaneous injection

• Available in 70 mg or 140 mg doses, using a prefilled autoinjector or syringe

Who it's for:

• Adults with episodic or chronic migraine

• Not used to treat acute migraine attacks (not a pain reliever)

Common side effects:

• Injection site reactions

• Constipation

• Muscle cramps or spasms

Rare but serious risks:

• Hypersensitivity reactions (rash, swelling)

• Worsening of constipation in some patients

Aimovig may be particularly helpful for those who haven't responded well to oral migraine preventives (like beta-blockers, antiepileptics, or antidepressants).